[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study

Ferner, Robin E; Golding, John F.; Smith, Michael A.; Calonje, Eduardo; Jan, Wajanat; Sanjayanathan, V.; O’Doherty, Michael

doi:10.1093/annonc/mdm450

Cited by 251 publications

(160 citation statements)

References 17 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…Noninvasive modalities that can reliably differentiate NF from MPNST would significantly contribute to the management of NF1 patients. Recently, FDG-PET has been shown by us and other investigators to be a promising noninvasive modality with the potential to differentiate malignant from benign tumors (30,31). Fig.…”

Section: Differentiating Nf From Mpnst Using Noninvasive Pet/ct Imagingmentioning

confidence: 99%

PTEN dosage is essential for neurofibroma development and malignant transformation

Gregorian

Nakashima

Dry

et al. 2009

Proc. Natl. Acad. Sci. U.S.A.

104

View full text Add to dashboard Cite

Section: Differentiating Nf From Mpnst Using Noninvasive Pet/ct Imagingmentioning

confidence: 99%

PTEN dosage is essential for neurofibroma development and malignant transformation

Gregorian

Nakashima

Dry

et al. 2009

Proc. Natl. Acad. Sci. U.S.A.

104

View full text Add to dashboard Cite

“…Although the cutoff values of SUVmax vary among such reports, many papers reported SUVmax values of 3-4 (10,(16)(17)(18)(19). In our study, malignant neurogenic tumors showed high FDG uptake and benign tumors showed low FDG uptake, and the SUVmax had 90.0% sensitivity, 91.7% specificity, and 98.3% accuracy with a cutoff value of 4.8.…”

Section: Discussionmentioning

confidence: 45%

Correlations between F-18 FDG PET/CT and pathological findings in soft tissue lesions

et al. 2013

View full text Add to dashboard Cite

“…Positron emission tomography (PET-CT) -PET-CT is of great value in monitoring lesions with the potential for malignant transformation in NF1, especially in the evaluation of the symptomatic plexiform neurofibromas 58 . Due to the frequency and severity of MPNST associated to NF1, PET-CT scan could be useful in the following situations: a) when the plexiform tumor growth is inconsistent with the child's growth track; b) in the presence of neurological deficit; c) changes in tumor texture; and finally d) when patient reports an inexplicable and progressive pain.…”

Section: Nf1 Imaging Studiesmentioning

confidence: 99%

Neurofibromatosis: part 2 – clinical management

Batista

Goloni-Bertollo

Costa

et al. 2015

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Part 1 of this guideline addressed the differential diagnosis of the neurofibromatoses (NF): neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis (SCH). NF shares some features such as the genetic origin of the neural tumors and cutaneous manifestations, and affects nearly 80 thousand Brazilians. Increasing scientific knowledge on NF has allowed better clinical management and reduced rate of complications and morbidity, resulting in higher quality of life for NF patients. Most medical doctors are able to perform NF diagnosis, but the wide range of clinical manifestations and the inability to predict the onset or severity of new features, consequences, or complications make NF management a real clinical challenge, requiring the support of different specialists for proper treatment and genetic counseling, especially in NF2 and SCH. The present text suggests guidelines for the clinical management of NF, with emphasis on NF1.Keywords: neurofibromatosis, neurofibromatosis type 1, neurofibromatosis type 2, schwannomatosis, Legius syndrome. resumo A primeira parte desta diretriz abordou o diagnóstico diferencial das neurofibromatoses (NF): neurofibromatose do tipo 1 (NF1), neurofibromatose do tipo 2 (NF2) e schwannomatose (SCH). As NF compartilham algumas características, como a origem neural dos tumores e sinais cutâneos, e afetam cerca de 80 mil brasileiros. O aumento do conhecimento científico sobre as NF tem permitido melhor manejo clínico e redução da morbidade das complicações, resultando em melhor qualidade de vida para os pacientes com NF. A maioria dos médicos é capaz de realizar o diagnóstico das NF, mas a variedade de manifestações clínicas e a dificuldade de se prever o surgimento e a gravidade de complicações, torna o manejo da NF um desafio para o clínico e envolve diferentes especialistas para o tratamento adequado e aconselhamento genético, especialmente a NF2 e a SCH. O presente texto sugere algumas orientações para o acompanhamento dos portadores de NF, com ênfase na NF1.Palavras-chave: neurofibromatoses, neurofibromatose 1, neurofibromatose 2, schwannomatose, síndrome de Legius. 532Arq Neuropsiquiatr 2015;73(6): [531][532][533][534][535][536][537][538][539][540][541][542][543] Part 1 of this guideline addressed differential diagnosis of the neurofibromatoses (NF): neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis (SCH) 1 . This second part aims to offer some practical suggestions on the clinical management of NF.NF shares some features, such as the genetic origin of the neural tumors, cutaneous manifestations, heterogeneous phenotype and unpredictable and usually progressive natural course. However, they differ in age of onset, progression of the symptoms and prognosis. Moreover, NF clinical presentation and severity vary among patients and even between twins carrying the same NF gene mutation 2 . The wide range of NF clinical manifestations and the difficulties to predict the onset or the severity of new features, consequences, o...

show abstract

[18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study

Abstract: FDG PET and PET CT is a sensitive and specific diagnostic tool for NF1-associated MPNST. Other PET tracers will be required to solve the problem of predicting tumour grade.

Cited by 251 publications

References 17 publications

PTEN dosage is essential for neurofibroma development and malignant transformation

PTEN dosage is essential for neurofibroma development and malignant transformation

Correlations between F-18 FDG PET/CT and pathological findings in soft tissue lesions

Neurofibromatosis: part 2 – clinical management

Contact Info

Product

Resources

About